Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00610363 · ClinicalTrials.gov registry record · Phase 2
Study of the Safety and Effectiveness of Rilonacept for the Prevention of Gout Flares
A Phase 2 study, sponsored by Regeneron Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 83
- Enrollment target
NCT00610363 is a Phase 2 study that has completed, run by Regeneron Pharmaceuticals. The registered enrollment target is 83 participants.
The verdict
NCT00610363, a Phase 2 study, has completed, sponsored by Regeneron Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 83 participants
- Enrollment target
Study Summary
This was a clinical research study to determine the safety and effectiveness of an experimental drug called rilonacept in participants with gout who were beginning another additional treatment. Participants participated in this study for approximately 24 weeks. Rilonacept was being studied for use in preventing gout attacks in participants who had gout.
Interventions
- OTHER Placebo (for Rilonacept)
- BIOLOGICAL Rilonacept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 83 participants |
| Start Date | 2007-11 |
| Est. Completion | 2008-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00610363
The ClinicalTrials.gov registry entry for NCT00610363 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 83 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo (for Rilonacept) is the first listed.
NCT00610363 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00610363 about?
NCT00610363 is a clinical study titled "Study of the Safety and Effectiveness of Rilonacept for the Prevention of Gout Flares". This was a clinical research study to determine the safety and effectiveness of an experimental drug called rilonacept in participants with gout who were beginning another additional treatment. Participants participated in this study for approximately 24 weeks. Rilonacept was being studied for use i...
What is the current status of trial NCT00610363?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 83 participants. The study started on 2007-11. Estimated completion is 2008-10.
What interventions are being tested in trial NCT00610363?
The interventions under investigation include: Placebo (for Rilonacept) (OTHER), Rilonacept (BIOLOGICAL).
Who is sponsoring clinical trial NCT00610363?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.